Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis

doi:10.1158/0008-5472.CAN-08-4372

Cancer Res. Author manuscript; available in PMC 2010 August 15.

Published in final edited form as:

Cancer Res. 2009 August 15; 69(16): 6482–6489.

Published online 2009 August 4. doi: 10.1158/0008-5472.CAN-08-4372

PMCID: PMC2758272

NIHMSID: NIHMS128417

Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis

Claire M. Vajdic,¹ Michael O. Falster,^1,² Silvia de Sanjose,^3,⁴ Otoniel Martínez-Maza,⁵ Nikolaus Becker,⁶ Paige M. Bracci,⁷ Mads Melbye,⁸ Karin Ekström Smedby,⁹ Eric A. Engels,¹⁰ Jennifer Turner,¹¹ Paolo Vineis,¹² Adele Seniori Costantini,¹³ Elizabeth A. Holly,⁷ Eleanor Kane,¹⁴ John J. Spinelli,¹⁵ Carlo La Vecchia,¹⁶ Tongzhang Zheng,¹⁷ Brian C.-H. Chiu,¹⁸ Luigino Dal Maso,¹⁹ Pierluigi Cocco,²⁰ Marc Maynadié,²¹ Lenka Foretova,²² Anthony Staines,²³ Paul Brennan,²⁴ Scott Davis,²⁵ Richard Severson,²⁶ James R. Cerhan,²⁷ Elizabeth C. Breen,²⁸ Brenda Birmann,²⁹ Wendy Cozen,³⁰ and Andrew E. Grulich²

¹UNSW Cancer Research Centre, Prince of Wales Clinical School, University of New South Wales, Sydney, Australia

²National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia

³Epidemiologia i Registre del Càncer, Institut Català d' Oncologia, Barcelona, Spain

⁴CIBER Epidemiologia y Salud Publica, Barcelona, Spain

⁵Departments of Obstetrics & Gynecology and Microbiology, Immunology and Molecular Genetics, UCLA AIDS Institute and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

⁶Division of Clinical Epidemiology, German Cancer Research Centre, Heidelberg, Germany

⁷Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco CA, USA

⁸Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark

⁹Department of Medicine, Clinical Epidemiology Unit, and Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

¹⁰Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville MD, USA

¹¹Department of Anatomical Pathology, St Vincent’s Hospital, Sydney, Australia

¹²Environmental Epidemiology, Imperial College London, London, UK

¹³Occupational and Environmental Epidemiology Unit, Institute for Study and Prevention of Cancer, Florence, Italy

¹⁴Epidemiology & Genetics Unit, Department of Health Sciences, University of York, York, UK

¹⁵Cancer Control Research Program, BC Cancer Agency, Vancouver, British Columbia, Canada

¹⁶Istituto di Ricerche Farmacologiche “Mario Negri” and Istituto di Statistica Medica e Biometria, Università degli Studi di Milano, Milan, Italy

¹⁷Department of Epidemiology and Public Health, Yale School of Medicine, New Haven CT, USA

¹⁸Department of Health Studies, University of Chicago, Chicago IL, USA

¹⁹Epidemiology and Biostatistics Unit, Aviano Cancer Centre, Aviano, Italy

²⁰Department of Public Health, Occupational Health Section, University of Cagliari, Cagliari, Italy

²¹Registry of Hematological Malignacies of Cote d’Or, Dijon University Hospital, Dijon, France

²²Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic

²³School of Nursing, Dublin City University, Dublin, Ireland

²⁴International Agency for Research on Cancer, Lyon, France

²⁵Fred Hutchinson Cancer Research Centre & School of Public Health and Community Medicine, University of Washington, Seattle WA, USA

²⁶Department of Family Medicine and Karmanos Cancer Institute, School of Medicine, Wayne State University, Detroit MI, USA

²⁷Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester MN, USA

²⁸Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles CA, USA

²⁹Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

³⁰Keck School of Medicine, Department of Preventive Medicine, University of Southern California, Los Angeles CA, USA

Corresponding author: Claire M. Vajdic PhD, UNSW Cancer Research Centre, Prince of Wales Clinical School, University of New South Wales, Level 1 South Wing Edmund Blacket Building, Prince of Wales Hospital, Randwick NSW 2031, Australia. Phone +61 2 9382 8881. Fax +61 2 9382 8885. Email claire.vajdic/at/unsw.edu.au

The publisher's final edited version of this article is available free at Cancer Res

See other articles in PMC that cite the published article.

Abstract

We performed a pooled analysis of data on atopic disease and risk of non-Hodgkin lymphoma (NHL) from 13 case-control studies, including13,535 NHL cases and 16,388 controls. Self-reported atopic diseases diagnosed two or more years before NHL diagnosis (cases) or interview (controls) were analyzed. Pooled odds ratios (OR) and 95% confidence intervals were computed in two-stage random-effects or joint fixed-effects models, adjusted for age, sex, and study center. When modeled individually, lifetime history of asthma, hay fever, a specific allergy (excluding hay fever, asthma and eczema), and food allergy were associated with a significant reduction in NHL risk, and there was no association for eczema. When each atopic condition was included in the same model, reduced NHL risk was only associated with history of allergy (OR 0.80, 95% CI 0.68–0.94), and reduced B-cell NHL risk was associated with history of hay fever (OR 0.85, 95% CI 0.77–0.95) and allergy (OR 0.84, 95% CI 0.76–0.93). Significant reductions in B-cell NHL risk were also observed in individuals who were likely to be truly or highly atopic - those with hay fever, allergy or asthma and at least one other atopic condition over their lifetime. The inverse associations were consistent for the diffuse large B-cell and follicular subtypes. Eczema was positively associated with lymphomas of the skin; misdiagnosis of lymphoma as eczema is likely, but progression of eczema to cutaneous lymphoma cannot be excluded. This pooled study demonstrates evidence of a modest but consistent reduction in the risk of B-cell NHL associated with atopy.

Keywords: non-Hodgkin lymphoma, atopy, case-control, pooled analysis, risk

Introduction

A causal explanation for most cases of non-Hodgkin lymphoma (NHL) remains elusive. Given the established positive association between immune deficiency and NHL risk (1), and the origin of NHL from cells of the immune system, it is plausible that other forms of immune dysregulation, such as atopic disease, are also related to lymphoma. Case-control study results have been mixed (2–23), although recent studies predominantly have found a reduced risk of NHL in association with a history of atopy. In contrast, cohort studies, mostly of limited power and with few detailed questions on atopy, have found no consistent evidence of an association.(24–33)

Herein we report results from an international pooled analysis of case-control studies that examined history of self-reported atopic disease and risk of NHL.

Materials and methods

Study population

We performed a pooled analysis of data from 13 case-control studies identified through the InterLymph Consortium (www.epi.grants.cancer.gov/InterLymph). Participating studies (Table 1) met the following eligibility criteria: cases diagnosed with incident histologically confirmed NHL as adults (age 16–96 years); collection of personal history of 1 or more atopic conditions; and electronic data set available in March of 2007. Due to variations in study design between the six EpiLymph centers (Table 1), this study was treated statistically as six separate studies, to allow for assessment of center-specific effects and heterogeneity. Organ transplant recipients and individuals with HIV-infection, as well as hospital-based controls admitted for atopic conditions (n=39, 1.1%), were excluded.

Table 1

Characteristics of case-control studies participating in the pooled analysis of history of atopic disease and risk of non-Hodgkin lymphoma (NHL)

Exposure assessment

All studies ascertained self-reported history of atopy. Reports of atopic disease onset less than 2 years prior to NHL diagnosis (cases) or interview (controls) were excluded. This was necessary because an effect of increased medical surveillance in the period prior to case diagnosis could not be ruled out, and it also partially reduced the possibility that subclinical disease influenced exposure.

Given the recognized potential for misclassification of self-reported history of atopic disease (34), we constructed variables to represent participants who were likely to be truly atopic (35–37). These exposures were: atopic disease of long duration and multiple atopic conditions during a lifetime (eczema was excluded post-hoc). These were defined a priori and we hypothesized they would be more strongly related to NHL risk.

Statistical analysis

Odds ratios (OR) and 95% confidence intervals (CI) were computed from unconditional logistic regression models, using a two-stage random-effects model to estimate relative risk (hereafter called ‘risk’) of NHL, and a joint fixed-effects model to estimate risk by NHL subtype.(38) All WHO classification (39) subtypes of NHL, except multiple myeloma, were included in the analysis, as recommended for epidemiological analyses (40). All models were adjusted for the matching variables age, sex, and region/study center. We first examined NHL risk in association with history of each individual atopic condition. We next examined NHL risk adjusted for history of each of the other atopic conditions, and thus included only the 12 study centers that collected data on all four major atopic conditions (asthma, hay fever, eczema and specific allergy). Third, we examined NHL risk in association with history of each individual condition alone, or with one or more other atopic conditions, and included studies that collected data on more than one atopic condition over a lifetime.

Heterogeneity among study centers was assessed using Cochran´s Q statistic and the I² statistic.(41) In the presence of significant heterogeneity (p<0.10), forest plots were used to identify outlying studies, and sensitivity analyses were performed with and without the outlying studies; no individual study was consistently identified as outlying. Due to a predominance of study participants of Caucasian origin, stratification by race was not meaningful. Restriction to Caucasians gave similar results. All statistical tests were two-sided and assumed an α-error level of 0.05. Analyses were performed using the STATA software version 10.0 (Stata Corporation, College Station, TX).

The pooled analyses were approved by the University of New South Wales Human Research Ethics Committee.

Results

The sex distribution for the pooled cases (n=13,535) and controls (n=16,388) was similar (Table 2). However, compared to controls, cases were more likely to be older (p<0.0001), of lower socioeconomic status (p<0.0001), and of mixed race (p=0.001), and less likely to be black (p=0.006), although race was specified for fewer than 50% of participants (Table 2).

Table 2

Demographic and tumor characteristics of the pooled study participants

There was no statistically significant heterogeneity among studies for asthma (p=0.70, I²=0%) or hay fever (p=0.15, I²=28%), but there was for eczema (p=0.03, I²=46%; Figure 1). For allergies to specific substances, between-study heterogeneity was also evident for the summary measure ‘any specific allergy’ (p<0.001, I²=63%; Figure 1), allergy to one or more foods (p<0.001, I²=77%), animals (p=0.06, I²=53%), and plants (p=0.01, I²=72%). Stratification by study design features, including questionnaire and data collection format, doctor-diagnosed versus self-identified atopic disease, source of controls, response rates, and control exposure prevalence did not reveal any systematic or statistically significant differences between strata in the pooled estimates for any of the atopic conditions (data not shown). Hence, all studies were retained in the pooled analyses. Reassuringly, as described below, exclusion of outlying studies did not alter the significance of the pooled risk estimates.

Figure 1

Estimates of NHL risk restricted to individuals with a history of the atopic disease diagnosed at least 2 years prior to interview/NHL diagnosis, sorted by atopic disease prevalence in controls. Individual study odds ratios (OR, filled diamonds) and 95% (more ...)

Considering only studies that ascertained history of all 4 major atopic diseases, 767 (69%) controls with asthma also reported another atopic condition; 52% also had hay fever, 19% eczema and 43% a specific allergy. Of controls with hay fever, 1,556 (57%) also reported another atopic condition (21% asthma, 16% eczema and 45% specific allergy). Of controls with eczema, 333 (51%) also reported another atopic condition (23% asthma, 30% hay fever and 34% specific allergy), while 1,434 (57%) of controls with a specific allergy also reported another atopic condition (19% asthma, 47% hay fever and 15% eczema).

Asthma

A history of asthma was associated with a significant 10% reduction in risk of NHL (Figure 1). In the 12 studies that collected data on all 4 atopic conditions, the OR was not significant after adjustment for history of the other atopic conditions (Table 3). NHL risk was not attenuated in those who only experienced asthma (Table 4), and a significant reduction in NHL risk, and B-cell NHL risk, was observed in individuals with asthma and at least one other atopic condition during their lifetime (Table 4). After adjustment for history of other atopic conditions, the OR was 1.08 (95% CI 0.73–1.58) for those with asthma for up to 5 years, 0.80 (95% CI 0.51–1.27) for 6–10 years and 0.80 (95% CI 0.56–1.13) for more than 10 years.

Table 3

The pooled relative risk of non-Hodgkin lymphoma (NHL) for a personal history of individual atopic conditions, adjusted by history of other atopic disease

Table 4

The pooled relative risk of non-Hodgkin lymphoma (NHL) for a personal history of individual atopic conditions, alone or in combination with at least one other specified atopic disease

Hay fever

Risk of NHL was reduced by 18% in participants with a history of hay fever (Figure 1), but the reduction in risk was not significant in a model that adjusted for history of the other atopic conditions (Table 3). History of hay fever was significantly inversely associated with risk of B-cell NHL, diffuse large B-cell (DLBCL), and follicular NHL after adjustment by history of the other atopic conditions (Table 3). NHL risk was reduced in those who only experienced hay fever and a significant reduction in risk of all NHL, B-cell NHL, DLBCL and follicular NHL was observed in those with hay fever and one or more other atopic conditions during their lifetime (Table 4). After adjustment by history of other atopic conditions, the OR was 1.31 (95% CI 0.86–2.00) for those with hay fever for up to 5 years, 1.48 (95% CI 0.96–2.28) for 6–10 years and 0.78 (95% CI 0.63–0.97) for more than 10 years.

Eczema

Risk of NHL was not associated with a history of eczema (Figure 1) and excluding the single potential outlying study responsible for the between-study heterogeneity did not materially alter the pooled risk (OR 1.03, 95% CI 0.89–1.19; p_het=0.10, I²=35%). A history of eczema was also not associated with NHL risk after adjustment for history of the other atopic conditions (Table 3), or alone or with a history of one or more other atopic diseases (Table 4). A history of eczema and at least one other condition was inversely associated with risk of DLBCL (Table 4); no other B-cell subtypes were associated with eczema (Table 3 and Table 4). The ORs from the model adjusted for history of other atopic conditions were 1.11 (95% CI 0.82–1.50) for individuals with eczema for up to 5 years, 0.88 (95% CI 0.56–1.38) for 6–10 years and 0.88 (95% CI 0.68–1.13) for more than 10 years.

Eczema was associated with a significant 2-fold increased risk of T-cell NHL (Table 3 and Table 4), due to an excess risk of mycoses fungoides/Sézary syndrome (MF/SS, number (n) of exposed cases=26; OR 2.62, 95% CI 1.64–4.17) and the peripheral T-cell subtype angioimmunoblastic lymphoma (n=6; OR 2.60, 95% CI 1.02–6.62). Risk of primary cutaneous CD30-positive T-cell lymphoma was non-significantly elevated (n=4; OR 2.56, 95% CI 0.66–9.99). Although the estimates in association with duration of eczema were imprecise, the greatest excess risk of MF/SS was observed in those with a 6–10 year history of eczema (n=3; OR 5.51, 95% CI 1.55–19.56,); the OR for duration <5 years was 1.63 (95% CI 0.38–7.05; n=2) and for duration >10 years 3.15 (95% CI 1.26–7.85; n=6). Eczema also was associated with an increased risk of overall NHL that originated in the skin (OR 2.09, 95% CI 1.19–3.69), but not at the non-skin sites (OR 1.00, 95% CI 0.81–1.23).

Any specific allergy

A history of one or more specific allergies was associated with a significant 20% reduction in NHL risk (Figure 1). In a sensitivity analysis excluding the two outlying studies responsible for the between-study heterogeneity, the pooled OR was slightly weakened (OR 0.88, 95% CI 0.81–0.95; p_het=0.73, I²=0%). In the 12 studies that collected data on all 4 atopic conditions, NHL risk was significantly reduced in individuals with a history of allergy when adjusted for lifetime history of other atopic conditions (Table 3). Significant inverse associations also were observed for B-cell NHL and DLBCL (Table 3). NHL risk was significantly reduced in those who experienced allergy alone, as well as those who experienced allergy and at least one other atopic condition (Table 4). This association was significant for B-cell NHL, DLBCL, and follicular NHL. The ORs obtained from the model adjusted for history of other atopic conditions were 1.38 (95% CI 0.68–2.79) for those with allergy for up to 5 years, 1.67 (95% CI 0.44–6.28) for 6–10 years and 0.76 (95% CI 0.45–1.29) for more than 10 years.

Food allergy was the only specific allergy significantly associated with overall NHL risk. Risk of NHL was reduced by 25% (Figure 1), and removing the three studies responsible for the between-study heterogeneity had a negligible effect on the pooled estimate (OR 0.81, 95% CI 0.70–0.94). NHL risk remained significantly reduced (OR 0.60, 95% CI 0.40–0.91) after adjustment for lifetime history of other atopic conditions. An inverse association also was observed for B-cell NHL (OR 0.65, 95% CI 0.55–0.77), DLBCL (OR 0.67, 95% CI 0.52–0.86) and follicular lymphomas (OR 0.62, 95% CI 0.47–0.80).

The fully adjusted pooled ORs for all NHL were 1.05 (95% CI 0.81–1.38) for history of animal allergy, OR 1.33 (95% CI 0.57–3.10) for plant allergy, 0.91 (95% CI 0.67–1.23) for insect allergy, and 0.93 (95% CI 0.80–1.07) for ‘other allergy’ (data not shown in tables). Other than a reduced risk of marginal zone lymphoma associated with a history of ‘other allergy’ (OR 0.56, 95% CI 0.35–0.90), there were no significant subtype associations for these exposures.

Multiple atopic conditions

A history of any one atopic condition (asthma, hay fever or any specific allergy) was associated with a significant reduction in NHL risk (OR 0.87, 95% CI 0.82–0.93). Risk was further reduced for any two (OR 0.81, 95% CI 0.70–0.94) or all three of these conditions (OR 0.58, 95% CI 0.42–0.78) and the trend with increasing number of conditions was significant (p_trend<0.0001). When restricted to B-cell NHL, the results were very similar (data not shown). Amongst those with a history of all three conditions, risks for DLBCL, follicular and CLL/SLL/PLL/MCL lymphomas were reduced by 47–51% (data not shown). There were no cases of MCL with a history of 3 atopic conditions.

Discussion

In this large-scale, international pooled analysis, a personal history of atopy at any time of life was associated with a small reduction in NHL risk. History of a specific allergy, food allergy in particular, independently predicted risk of NHL, and history of a specific allergy or hay fever independently predicted risk of B-cell NHL. Asthma was inversely associated with overall and B-cell NHL risk in individuals who reported at least one other atopic condition. The observed inverse associations were consistent for the DLBCL and follicular subtypes. The specificity of the effect for B-cell lymphomas and the strengthening of the effect with exposure histories that were less likely to be misreported, such as individuals with multiple atopic diseases, support an effect of atopy on risk of NHL.

Case-control studies of NHL risk in relation to personal history of asthma, hay fever, and specific allergies that were not included in these pooled analyses have shown varied results, and none adjusted for history of other atopic diseases.(2–9, 13, 14, 19) Of these 11 studies, three reported a significant increased risk of NHL (two with eczema (3, 5) and one with hives (13)), while three reported a significant decreased risk of NHL (two with eczema (8, 13) and one with asthma (19)). The eight cohort studies reported similarly mixed findings, although many were null.(24–31) Three reported a significant increased risk, one with hives (25), one with any specific allergy (26) and one with childhood eczema (30), while one reported a significant decreased risk of NHL with asthma (28). Across all studies, there was no pattern to the direction of the null findings.

The predominance of null findings in cohort studies is not unexpected given that most of these studies had limited power and assessed risk only in relation to atopic disease history at any time of life. Only two studies assessed risk in relation to history of multiple atopic diseases.(26, 31) One reported an OR of 0.94 (95% CI 0.74–1.19) for a history of both asthma and hay fever (31); that study, though well powered, examined deaths from NHL, rather than incident NHL. The other study reported a non-significant excess risk in association with a history of multiple allergies, based on 46 incident haematopoietic tumors.(26, 31)

Atopic diseases are characterized by immediate hypersensitivity reactions, initiated by the interaction of IgE antibodies (produced by B-cells) with foreign antigens (allergens), leading to a reaction that involves the release of many inflammatory molecules, cytokines and chemokines. (42) Our finding of a reduced risk of B-cell but not T-cell NHL in persons with a history of atopic disease is consistent with an inverse association between such Ig-mediated immune allergic responses and NHL risk. The heightened response to antigens that is manifested as atopy may also be associated with a heightened response to cancer-specific or cancer-associated antigens, and thus with a reduced risk of NHL. Several features of atopic responses have the potential to inhibit tumor cell growth. IgE can enhance antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis, antigen presentation, and mast cell responses.(43) The high affinity of the Fc receptors (including CD23) for IgE makes antibodies of the IgE subclass effective at mediating ADCC and allows enhanced antigen-presentation, potentially promoting the generation of anti-tumor cytotoxic T cells. (43, 44) Additionally, eosinophils can mediate cellular cytotoxicity directly, and mast cells produce a wide range of mediators that can exert direct cytotoxic and growth-inhibitory effects on tumor cells. (43, 45, 46)

Whereas atopy is associated with the production of antibodies of the IgE subclass by B cells, some features of allergic responses, including induced immunoregulatory mechanisms, may result in the inhibition of B-cell activation. Such inhibition could decrease the occurrence of lymphomagenic molecular lesions (chromosomal translocation, oncogene mutation) that result from somatic DNA-modifying events that occur in germinal cell (GC) B-cells following activation, such as Ig class-switch recombination and somatic hypermutation.(47) In light of evidence that most B-cell NHLs are of GC or post-GC origin (48), a role for an allergy-associated decrease in such lymphomagenic molecular lesions is possible. However, we did not have sufficient biological data from a representative sample to test the hypothesis that only those NHLs that had undergone somatic hypermutation or class switching would be inversely associated with atopy.

The observed increased risk of cutaneous lymphoma (MF/SS) associated with a history of eczema may be an artifact of early misdiagnosis of some cutaneous lymphomas as eczema. Cutaneous lymphomas are difficult to diagnose, both clinically and histopathologically, but are thought to develop slowly over years to decades. The typical duration of eczema prior to T-cell NHL diagnosis in our pooled population was 6–10 years. MF/SS presents initially as patches, plaques, and/or tumors, and some early skin lesions may mimic eczema.(49) While there is no published evidence that persistent eczema is a precursor to MF/SS, we are unable to exclude this possibility.

A key strength of these pooled analyses is the large sample size, enabling the detection of weak to modest associations. Other strengths include the examination of risk by NHL subtype, of confounding, of influence by study design factors, and of risk in sub-groups of individuals who are likely to be truly atopic. However, as the analyses by B-cell subtype were exploratory, the possibility of chance associations due to multiple comparisons cannot be excluded. The consistency of the findings for the major B-cell types is nevertheless reassuring. In addition, this study modeled risk adjusted for history of other atopic conditions and this was shown to be necessary to avoid confounded associations due to the co-occurrence of atopic disease.

A limitation common to case-control studies is the retrospective collection of self-reported atopic histories with its inherent potential for selection bias, misclassification, and recall bias. Seven study centers had a large (>20%) differential in their case and control participation rates. However, the pooled estimates were unchanged when stratified by control participation rate or control source (population versus hospital), arguing against a strong contribution by selection bias. Furthermore, the magnitude and the rank order of the control prevalence of different atopic conditions were largely consistent with published population-based prevalence surveys.(50, 51) Misclassification that is not expected to be differential, may have contributed to the modest and null associations observed for some exposures. Self-reported hay fever, with its typical seasonal and well characterized symptoms, may be more reliable than self-reported asthma, but may still have been misclassified with plant allergies. Misclassification was addressed to some extent by analyzing risk in relation to duration and multiplicity of atopic disease. Recall bias due to a consistently greater under-reporting of atopic conditions by cases compared to controls cannot be excluded, particularly in light of the reported abatement of atopic symptoms with the development of haematopoietic neoplasms (2), especially for the less well defined conditions and for those with less severe symptoms. However, structured questionnaires, many of which asked about specific times over the life course and details of the type of allergy and use of medications, would be expected to minimize this potential bias. Furthermore, recall bias is less likely to explain the observed associations with multiple atopic conditions. However, the magnitude of the effect was weak to modest, and thus we cannot exclude the possibility that a moderately strong confounder present in most of the pooled studies could account for the association.

In summary, we found that atopic disease history is associated with a weak to moderate reduction in the risk of B-cell NHL. The inverse association was consistent for specific allergies, hay fever, and multiple atopic diseases, but was not observed for eczema or for asthma independent of other atopic diseases. Investigation of the genetic and environmental factors underlying atopy and its apparent inverse association with NHL risk will inform our understanding of the complex biological pathways that may be involved. Large-scale cohort study data assessing a range of measures of atopic phenotype throughout life, in addition to serial assessment of specific IgE at least 10 years prior to NHL diagnosis, are required to confirm these findings.

Acknowledgments

The pooled analysis was funded by the Leukaemia Foundation of Australia (LFA GIA 24). Individual studies were supported by the Italian Association for Cancer Research and the Italian League Against Cancer (Avi-N, Northern Italy); the Canadian Cancer Society through the National Cancer Institute of Canada, the Canadian Institutes for Health Research and the Chan Sisters Foundation (British Columbia); National Cancer Institute (CA62006) (Connecticut); European Commission (QLK4-CT-2000-00422) (EpiLymph); Association pour la Recherche contre le Cancer (5111) and Fondation de France (1999 008471) (EpiLymph-France); Compagnia di San Paolo di Torino, Programma Oncologia 2001 (EpiLymph-Italy); Health Research Board (EpiLymph-Ireland); Spanish Ministry of Health FISS (PI040091) and CIBERESP (06/06/0073) (EpiLymph-Spain); German Federal Office for Radiation Protection (StSch4261 and StSch4420) (EpiLymph-Germany); National Institutes of Health (CA51086), the European Community and the Italian League against Cancer (Italy); National Cancer Institute (CA92153) (Mayo); National Cancer Institute (PC65064, PC67008, PC67009, PC67010, PC71105) (NCI-SEER); American Institute for Cancer Research (99B083) (Nebraska); National Health and Medical Research Council of Australia (990920) (NSW); National Institutes of Health (CA69269-02) and the Swedish Cancer Society (04 0458) (SCALE); National Institutes of Health (CA45614, CA89745, CA87014, CA104682) (UCSF); and the Leukaemia Research Fund of Great Britain (UK). The funders did not participate in the design, data collection or analyses of the individual studies, or in the interpretation and writing of manuscripts.

Dr Vajdic is supported by a National Health and Medical Research Council Career Development Award (ID 510346) and a Cancer Institute NSW Career Support and Development Fellowship (ID 07-CDF-1/38). Dr. Martínez-Maza received support from the National Institutes of Health (CA121195).

List of abbreviations


DLBCL	Diffuse large B-cell lymphoma

CLL	Chronic lymphocytic leukemia

CI	Confidence interval

MALT	Mucosa-associated lymphoid tissue

MCL	Mantle cell lymphoma

NHL	Non-Hodgkin lymphoma

OR	Odds ratio

PLL	Prolymphocytic lymphoma

SLL	Small lymphocytic lymphoma

Ig	immunoglobulin

GC	germinal center.

References

1. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet. 1991;337:805–809. [PubMed]

2. McCormick DP, Ammann AJ, Ishizaka K, Miller DG, Hong R. A study of allergy in patients with malignant lymphoma and chronic lymphocytic leukemia. Cancer. 1971;27:93–99. [PubMed]

3. Bernard SM, Cartwright RA, Bird CC, Richards ID, Lauder I, Roberts BE. Aetiologic factors in lymphoid malignancies: a case-control epidemiological study. Leuk Res. 1984;8:681–689. [PubMed]

4. Tielsch JM, Linet MS, Szklo M. Acquired disorders affecting the immune system and non-Hodgkin’s lymphoma. Prev Med. 1987;16:96–106. [PubMed]

5. Cartwright RA, McKinney PA, O'Brien C, et al. Non-Hodgkin's? lymphoma: case control epidemiological study in Yorkshire. Leuk Res. 1988;12:81–88. [PubMed]

6. Franceschi S, Serraino D, Bidoli E, et al. The epidemiology of non-Hodgkin's lymphoma in the north-east of Italy: a hospital-based case-control study. Leuk Res. 1989;13:465–472. [PubMed]

7. La Vecchia C, Negri E, Franceschi S. Medical history and the risk of non-Hodgkin's lymphomas. Cancer Epidemiol Biomarkers Prev. 1992;1:533–536. [PubMed]

8. Bernstein L, Ross RK. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res. 1992;52:5510s, 5515s. [PubMed]

9. Doody MM, Linet MS, Glass AG, et al. Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control. 1992;3:449–456. [PubMed]

10. Holly EA, Lele C, Bracci PM, McGrath MS. Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol. 1999;150:375–389. [PubMed]

11. Vineis P, Crosignani P, Sacerdote C, et al. Haematopoietic cancer and medical history: a multicentre case control study. J Epidemiol Community Health. 2000;54:431–436. [PMC free article] [PubMed]

12. Tavani A, La Vecchia C, Franceschi S, Serraino D, Carbone A. Medical history and risk of Hodgkin's and non-Hodgkin's lymphomas. Eur J Cancer Prev. 2000;9:59–64. [PubMed]

13. Fabbro-Peray P, Daures JP, Rossi JF. Environmental risk factors for non-Hodgkin's lymphoma: a population-based case-control study in Languedoc-Roussillon, France. Cancer Causes Control. 2001;12:201–212. [PubMed]

14. Briggs NC, Levine RS, Brann EA. Allergies and risk of non-Hodgkin's lymphoma by subtype. Cancer Epidemiol Biomarkers Prev. 2002;11:401–407. [PubMed]

15. Holly EA, Bracci PM. Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco. Am J Epidemiol. 2003;158:316–327. [PubMed]

16. Zhang Y, Holford TR, Leaderer B, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control. 2004;15:419–428. [PubMed]

17. Becker N, Deeg E, Rudiger T, Nieters A. Medical history and risk for lymphoma: results of a population-based case-control study in Germany. Eur J Cancer. 2005;41:133–142. [PubMed]

18. Grulich AE, Vajdic CM, Kaldor JM, et al. Birth order, atopy, and risk of non-Hodgkin lymphoma. J Natl Cancer Inst. 2005;97:587–594. [PubMed]

19. Soderberg KC, Jonsson F, Winqvist O, Hagmar L, Feychting M. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer. 2006;42:3028–3033. [PubMed]

20. Bracci PM, Dalvi TB, Holly EA. Residential history, family characteristics and non-Hodgkin lymphoma, a population-based case-control study in the San Francisco Bay Area. Cancer Epidemiol Biomarkers Prev. 2006;15:1287–1294. [PubMed]

21. Becker N, de Sanjose S, Nieters A, et al. Birth order, allergies and lymphoma risk: results of the European collaborative research project Epilymph. Leuk Res. 2007;31:1365–1372. [PubMed]

22. Cozen W, Cerhan JR, Martinez-Maza O, et al. The effect of atopy, childhood crowding, and other immune-related factors on non-Hodgkin lymphoma risk. Cancer Causes Control. 2007;18:821–831. [PubMed]

23. Melbye M, Smedby KE, Lehtinen T, et al. Atopy and risk of non-Hodgkin lymphoma. J Natl Cancer Inst. 2007;99:158–166. [PubMed]

24. Robinette CD, Fraumeni JF., Jr Asthma and subsequent mortality in World War II veterans. J Chronic Dis. 1978;31:619–624. [PubMed]

25. McWhorter WP. Allergy and risk of cancer. A prospective study using NHANESI followup data. Cancer. 1988;62:451–455. [PubMed]

26. Mills PK, Beeson WL, Fraser GE, Phillips RL. Allergy and cancer: organ site-specific results from the Adventist Health Study. Am J Epidemiol. 1992;136:287–295. [PubMed]

27. Vesterinen E, Pukkala E, Timonen T, Aromaa A. Cancer incidence among 78,000 asthmatic patients. Int J Epidemiol. 1993;22:976–982. [PubMed]

28. Kallen B, Gunnarskog J, Conradson TB. Cancer risk in asthmatic subjects selected from hospital discharge registry. Eur Respir J. 1993;6:694–697. [PubMed]

29. Talbot-Smith A, Fritschi L, Divitini ML, Mallon DF, Knuiman MW. Allergy, atopy, and cancer: a prospective study of the 1981 Busselton cohort. Am J Epidemiol. 2003;157:606–612. [PubMed]

30. Soderberg KC, Hagmar L, Schwartzbaum J, Feychting M. Allergic conditions and risk of hematological malignancies in adults: a cohort study. BMC Public Health. 2004;4:51. [PMC free article] [PubMed]

31. Turner MC, Chen Y, Krewski D, Ghadirian P, Thun MJ, Calle EE. Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol. 2005;162:212–221. [PubMed]

32. Lindelof B, Granath F, Tengvall-Linder M, Ekbom A. Allergy and cancer. Allergy. 2005;60:1116–1120. [PubMed]

33. Eriksson NE, Mikoczy Z, Hagmar L. Cancer incidence in 13811 patients skin tested for allergy. J Investig Allergol Clin Immunol. 2005;15:161–166. [PubMed]

34. Turner MC, Chen Y, Krewski D, Ghadirian P. An overview of the association between allergy and cancer. Int J Cancer. 2006;118:3124–3132. [PubMed]

35. Kurukulaaratchy RJ, Matthews S, Arshad SH. Defining childhood atopic phenotypes to investigate the association of atopic sensitization with allergic disease. Allergy. 2005;60:1280–1286. [PubMed]

36. Burgess JA, Walters EH, Byrnes GB, et al. Who remembers whether they had asthma as children? J Asthma. 2006;43:727–730. [PubMed]

37. Annesi-Maesano I, Beyer A, Marmouz F, Mathelier-Fusade P, Vervloet D, Bauchau V. Concurrent allergic diseases: a cross-sectional study in a French population. Allergy. 2006;61:390–391. [PubMed]

38. Stukel TA, Demidenko E, Dykes J, Karagas MR. Two-stage methods for the analysis of pooled data. Stats Med. 2001;20:2115–2130. [PubMed]

39. Jaffe ES, Stein H, Vardiman JW, editors. Lyon, France: IARC Press; 2001. Pathology and Genetics of Tumours of Hamatopoietic and Lymphoid Tissues.

40. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classificatin of lympoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood. 2007;110:695–708. [PubMed]

41. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stats Med. 2002;21:1539–1558. [PubMed]

42. Wasserman SI. Biochemical Mediators of Allergic Reactions. In: Grammer LC, Greenberger PA, editors. Patterson's Allergic Diseases. 6th edition ed. Lippincott Williams & Wilkins; 2002.

43. Jensen-Jarolim E, Achatz G, Turner MC, et al. AllergoOncology:the role of IgE-mediated allergy in cancer. Allergy. 2008;63:1255–1266. [PMC free article] [PubMed]

44. Gould HJ, Mackay GA, Karagiannis SN, et al. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol. 1999;29:3527–3537. [PubMed]

45. Strik MC, de Koning PJ, Kleijmeer MJ, et al. Human mast cells produce and release the cytotoxic lymphocyte associated protease granzyme B upon activation. Mol Immunol. 2007;44:3462–3472. [PubMed]

46. Wang H, Diepgen TL. Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy. 2005;60:1098–1111. [PubMed]

47. Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal centre-derived lymphomagenesis. Nature Genetics. 2008;40:108–112. [PubMed]

48. Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica. 2007;92:960–969. [PMC free article] [PubMed]

49. Keehn CA, Belongie IP, Shistik G, Fenske NA, Glass LF. The diagnosis, staging, and treatment options for mycosis fungoides. Cancer Control. 2007;14:102–111. [PubMed]

50. Woods RK, Abramson M, Bailey M, Walters EH. Comparisons arising from the European Community Respiratory Health Survey (ECRHS) 1991–1994. Eur J Clin Nutr. 2001;55:298–304. [PubMed]

51. Pearce N, Sunyer J, Cheng S, et al. Comparison of asthma prevalence in the ISAAC and the ECRHS. ISAAC Steering Committee and the European Community Respiratory Health Survey. International Study of Asthma and Allergies in Childhood. Eur Respir J. 2000;16:420–426. [PubMed]